Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Santhera’s partner Catalyst Pharmaceuticals launches Agamree (vamorolone) in the United States to treat Duchenne muscular dystrophy

Written by | 18 Mar 2024 | Genetics

Santhera Pharmaceuticals is pleased to note the launch of Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in the United States by Catalyst Pharmaceuticals, Inc. the Company’s commercialization partner for North America .

“Congratulations to our partner Catalyst on the launch of Agamree in the United States. Following the first global market introduction of this novel product in Germany in January, this launch represents an important next step in making Agamree available to as many patients with DMD as soon as possible,” said Dario Eklund, CEO of Santhera.

The launch of Agamree in the U.S. follows the approval of the product by the FDA on October 26, 2023, based on data from the pivotal VISION-DMD study, recently published in Neurology,(previously cited) and supplemented with safety information collected from three open-label studies, including extension studies.

According to the license agreement between the companies, first announced in June 2023, Catalyst holds an exclusive North American license to commercialize Agamree for DMD and all potential future indications. Under the agreement, Catalyst will pay Santhera sales-based milestones of up to $ 105 million as well as up to low-teen percentage royalties and will assume Santhera’s corresponding third-party royalty obligations on Agamree sales in all indications in North America.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.